Evidence map›Paper›PMID 36283895›Full record

ArticleVaccine2022

The decline in immunity and circulation of pertussis among Chinese population during the COVID-19 pandemic: A cross-sectional sero-epidemiological study.

Hanqing He, Yao Zhu, Mingjuan Jin, Yang Zhou, Xuewen Tang, Rui Yan, Xuan Deng, Kun Chen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hanqing HeDepartment of Epidemiology and Biostatistics at School of Public Health, Zhejiang University School of Medicine, Hangzhou, China; Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Yao ZhuDepartment of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Mingjuan JinDepartment of Epidemiology and Biostatistics at School of Public Health, Zhejiang University School of Medicine, Hangzhou, China.
Yang ZhouDepartment of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Xuewen TangDepartment of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Rui YanDepartment of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Xuan DengDepartment of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Kun ChenDepartment of Epidemiology and Biostatistics at School of Public Health, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: ck@zju.edu.cn.
Zhejiang Center for Disease Control and Prevention · CNZhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn recent years, the resurgence of pertussis has posed a public health challenge in many countries. This study aimed to evaluate the immunity levels against pertussis among populations of different ages in China.

methodsWe conducted a cross-sectional serological survey in Zhejiang Province, China in 2020. Serum IgG antibodies against pertussis toxin (anti-PT), filamentous hemagglutinin (anti-FHA), and pertactin (anti-PRN) were quantitatively measured. The geometric mean concentration (GMC) of three antibodies was calculated. An anti-PT level < 5 IU/mL was considered undetectable, ≥20 IU/mL as seropositive and ≥80 IU/mL as an indicator of recent infection. Mathematical models were fitted for anti-PT concentrations over time in children after four doses of the pertussis vaccination.

resultsA total of 4459 participants aged 0-59 years were included in the analyses. The overall positivity rate of anti-PT was 29.80% with the highest (81.44%) rate in the 1-2 years old and the lowest (4.72%) in 10-14 years old. The GMCs of anti-PT, anti-FHA and anti-PRN for the whole participants were 9.67 (95%CI: 9.25-10.10),18.93 (18.24-19.67), and 8.99 (8.61-9.38) IU/mL, respectively. Over 50% of subjects aged ≥ 7 years had undetectable anti-PT IgG antibodies (<5IU/mL). The proportions of the populations with anti-PT IgG ≥ 80 IU/mL were approximately 0.9%, 0.3% and 1.1% among the 10-14, 15-29, and 40-59 years old groups, respectively. The power regression equation of the attenuation model after last dose of pertussis vaccine was y = 41.088x

conclusionThe prevalence of pertussis decreased during the study period in the COVID-19 pandemic; however, there was still a certain proportion of adolescents and adults with evidence of recent infection. The decline in antibody levels after pertussis vaccination was observed, and booster doses are in urgent need in China.

Indexed as

COVID-19Whooping CoughAdolescentAdultAntibodies, BacterialChildChild, PreschoolChinaCross-Sectional StudiesHumansImmunoglobulin GInfantMiddle AgedPandemicsPertussis ToxinPertussis VaccineAntibodies, BacterialImmunoglobulin GPertussis ToxinPertussis VaccineAntibodyPertussisSeroprevalenceVaccine

Identifiers

PMID36283895
PMCPMC9581792
OpenAlexW4306932588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.